Distinguishing Post-translational Modifications in Dominantly Inherited Frontotemporal Dementias: FTLD-TDP Type A (GRN) Vs Type B (C9orf72)
Overview
Authors
Affiliations
Aims: Frontotemporal dementias are neuropathologically characterised by frontotemporal lobar degeneration (FTLD). Intraneuronal inclusions of transactive response DNA-binding protein 43 kDa (TDP-43) are the defining pathological hallmark of approximately half of the FTLD cases, being referred to as FTLD-TDP. The classification of FTLD-TDP into five subtypes (Type A to Type E) is based on pathologic phenotypes; however, the molecular determinants underpinning the phenotypic heterogeneity of FTLD-TDP are not well known. It is currently undetermined whether TDP-43 post-translational modifications (PTMs) may be related to the phenotypic diversity of the FTLDs. Thus, the investigation of FTLD-TDP Type A and Type B, associated with GRN and C9orf72 mutations, becomes essential.
Methods: Immunohistochemistry was used to identify and map the intraneuronal inclusions. Sarkosyl-insoluble TDP-43 was extracted from brains of GRN and C9orf72 mutation carriers post-mortem and studied by Western blot analysis, immuno-electron microscopy and mass spectrometry.
Results: Filaments of TDP-43 were present in all FTLD-TDP preparations. PTM profiling identified multiple phosphorylated, N-terminal acetylated or otherwise modified residues, several of which have been identified for the first time as related to sarkosyl-insoluble TDP-43. Several PTMs were specific for either Type A or Type B, while others were identified in both types.
Conclusions: The current results provide evidence that the intraneuronal inclusions in the two genetic diseases contain TDP-43 filaments. The discovery of novel, potentially type-specific TDP-43 PTMs emphasises the need to determine the mechanisms leading to filament formation and PTMs, and the necessity of exploring the validity and occupancy of PTMs in a prognostic/diagnostic setting.
Prion-like Spreading of Disease in TDP-43 Proteinopathies.
Pongracova E, Buratti E, Romano M Brain Sci. 2024; 14(11).
PMID: 39595895 PMC: 11591745. DOI: 10.3390/brainsci14111132.
Fontana E, Bongianni M, Benussi A, Bronzato E, Scialo C, Sacchetto L Alzheimers Dement. 2023; 20(2):1156-1165.
PMID: 37908186 PMC: 10917048. DOI: 10.1002/alz.13541.
Overlapping Neuroimmune Mechanisms and Therapeutic Targets in Neurodegenerative Disorders.
De Marchi F, Munitic I, Vidatic L, Papic E, Racki V, Nimac J Biomedicines. 2023; 11(10).
PMID: 37893165 PMC: 10604382. DOI: 10.3390/biomedicines11102793.
TDP-43 forms amyloid filaments with a distinct fold in type A FTLD-TDP.
Arseni D, Chen R, Murzin A, Peak-Chew S, Garringer H, Newell K Nature. 2023; 620(7975):898-903.
PMID: 37532939 PMC: 10447236. DOI: 10.1038/s41586-023-06405-w.
TDP-43 Proteinopathy Specific Biomarker Development.
Cordts I, Wachinger A, Scialo C, Lingor P, Polymenidou M, Buratti E Cells. 2023; 12(4).
PMID: 36831264 PMC: 9954136. DOI: 10.3390/cells12040597.